In recent trading, Monopar Therapeutics Inc (MNPR) saw its shares rise above the average analyst 12-month target price of $120.23, trading at $123.84 per share. This increase raises questions for investors regarding the future valuation of MNPR, especially since current analyst targets range from a low of $100 to a high of $133, with an average standard deviation of $11.351.
Analyst coverage for MNPR includes 13 targets, which recently noted 11 strong buy ratings, 1 buy rating, and 2 hold ratings. There were no sell or strong sell ratings recorded. The average rating among analysts stands at 1.36, where 1 represents a strong buy and 5 represents a strong sell, indicating overall positive sentiment despite slight fluctuations in ratings over the last few months.
Investors are urged to assess whether the current price reflects potential growth or if it has become overvalued, given its recent performance against analyst expectations.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
